Unknown

Dataset Information

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma.


ABSTRACT:

SUBMITTER: Thomas C 

PROVIDER: S-EPMC9851376 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature